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The transcription factor signal transducer and activator of transcription-1 (STAT1) plays a key role in immunity against
mycobacterial and viral infections. Here, we characterize three human STAT1 germline alleles from otherwise healthy
patients with mycobacterial disease. The previously reported L706S, like the novel Q463H and E320Q alleles, are
intrinsically deleterious for both interferon gamma (IFNG)–induced gamma-activating factor–mediated immunity and
interferon alpha (IFNA)–induced interferon-stimulated genes factor 3–mediated immunity, as shown in STAT1-deficient
cells transfected with the corresponding alleles. Their phenotypic effects are however mediated by different molecular
mechanisms, L706S affecting STAT1 phosphorylation and Q463H and E320Q affecting STAT1 DNA-binding activity.
Heterozygous patients display specifically impaired IFNG-induced gamma-activating factor–mediated immunity,
resulting in susceptibility to mycobacteria. Indeed, IFNA-induced interferon-stimulated genes factor 3–mediated
immunity is not affected, and these patients are not particularly susceptible to viral disease, unlike patients
homozygous for other, equally deleterious STAT1 mutations recessive for both phenotypes. The three STAT1 alleles are
therefore dominant for IFNG-mediated antimycobacterial immunity but recessive for IFNA-mediated antiviral
immunity at the cellular and clinical levels. These STAT1 alleles define two forms of dominant STAT1 deficiency,
depending on whether the mutations impair STAT1 phosphorylation or DNA binding.
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2(8): e131. DOI: 10.1371/journal.pgen.0020131
Introduction
Mendelian susceptibility to mycobacterial disease (MSMD)
is characterized by the occurrence of clinical disease caused
by weakly virulent mycobacteria in otherwise healthy
individuals (reviewed in [1,2]). This syndrome covers a broad
range of clinical phenotypes, reﬂecting the diversity of
environmental and host factors involved, notably the under-
lying genetic lesions. The ﬁve genes known to cause this
syndrome are involved in IL12/23-dependent interferon
gamma (IFNG)–mediated immunity. Two genes control the
production of IFNG: IL12B, encoding the p40 subunit of IL12
and IL23, and IL12RB1, encoding the b1 chain of the IL12 and
IL23 receptors (IL12RB1). Three genes control the response
to IFNG: IFNGR1 and IFNGR2, encoding the IFNG receptor
(IFNGR) chains, and STAT1, encoding the signal transducer
and activator of transcription-1 (STAT1). Allelic heteroge-
neity results in a total of 11 inherited disorders (Table 1):
recessive complete IL12p40 [3,4] and IL12RB1 deﬁciency with
[5] or without [6–8] surface-expressed receptors, recessive
complete IFNGR1 deﬁciency with [9] or without [10,11]
surface-expressed receptors, dominant [12] or recessive [13]
partial IFNGR1 deﬁciency, recessive complete IFNGR2
deﬁciency with [14] or without [15] surface-expressed
receptors, recessive partial IFNGR2 deﬁciency [16], and
dominant partial STAT1 deﬁciency [17]. Complete IFNGR1
and IFNGR2 deﬁciencies run a more severe clinical course
than the other defects, which are associated with residual
IFNG-mediated immunity [1,2,18,19].
The binding of homodimeric IFNG to its tetrameric
receptor leads to the activation of constitutively associated
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phosphorylate tyrosine residues in the intracellular part of
IFNGR1 (reviewed in [20–25]; Figure 1). Most latent STAT1
molecules reside in the cytosol as preassociated unphos-
phorylated homodimers [26–29]. Upon IFNG stimulation,
unphosphorylated STAT1 molecules are directly recruited to
IFNGR1 docking sites (centered on phosphorylated Y440)
[26,30]. They are then phosphorylated at Y701 and released
into the cytosol as phosphorylated STAT1 homodimers,
forming gamma-activating factors (GAFs), which are trans-
located to the nucleus [31]. GAF binds gamma-activating
sequences (GASs) present in the promoters of target genes
[32]. Following monomeric interferon alpha (IFNA) stimula-
tion, STAT2 is recruited to the phosphorylated IFNAR1 chain
of the heterodimeric IFNAR and is itself also phosphorylated
by JAK1 and TYK2 (reviewed in [20,22–25,33]; Figure 1). This
leads to the phosphorylated STAT2-mediated recruitment of
STAT1, which is then phosphorylated at Tyr-701. Active
phosphorylated STAT1/STAT2 heterodimers are released
into the cytosol and translocated to the nucleus with ISGF3G,
to form interferon-stimulated genes factor-3 (ISGF3) hetero-
trimers [34]. ISGF3 binds IFNA sequence response elements
(ISREs) in the promoters of target genes via the DNA-binding
domains of STAT1 and ISGF3G [35].
In humans, recessive complete STAT1 deﬁciency results in
impaired responses to both IFNG and IFNA [36,37]. It is
associated with a speciﬁc syndrome, different from MSMD, of
susceptibility to both mycobacteria (impaired IFNG-mediated
immunity) and viruses (impaired IFNA-mediated immunity).
The three known patients were unrelated and homozygous
for speciﬁc loss-of-function and loss-of-expression STAT1
mutations [36,37]. No STAT1 proteins were detected in the
patients’ cells and, accordingly, no activation of GAF and
ISGF3 was found in response to IFNG and IFNA, respectively.
The heterozygous relatives of these patients were healthy.
This contrasts with the heterozygous L706S STAT1 mutation
described in three patients from two kindreds with dominant
partial STAT1 deﬁciency and MSMD [17]. The L706S allele is
null (loss-of-function) for the activation of both GAF and
ISGF3, despite normal levels of STAT1 production. Intrigu-
ingly, this allele was found to be dominant for GAF activation
but recessive for ISGF3 activation. This accounted for the
patient’s clinical phenotype of mycobacterial but not viral
disease, but raised the question as to whether this genetic
curiosity was of general relevance. We report here two novel
STAT1 alleles associated with MSMD: E320Q and Q463H. Like
L706S, but by completely different mechanisms, these alleles
are dominant for IFNG-induced GAF-mediated but recessive
for IFNA-induced ISGF3-mediated immunity.
Results
Novel STAT1 Mutations in Two Kindreds
We investigated two unrelated children (P1 and P2) with a
mild form of MSMD (Figure 2A, case reports). The coding
Figure 1. Pathways of IFNG-Induced GAF-Mediated Immunity and IFNA-
Induced ISGF3-Mediated Immunity
Patients homozygous for null STAT1 mutations [36,37] suffer from both
mycobacterial and viral diseases. Patients heterozygous for STAT1
mutations L706S, Q463H, and E320Q suffer from mycobacterial but not
viral diseases ([17] and this report).
DOI: 10.1371/journal.pgen.0020131.g001
Table 1. Genetic Etiology of MSMD
Gene Inheritance Defect Protein References
IL12B AR C E  [3,4]
IL12RB1 AR C Eþ [5]
AR C E  [6,7,8]
IFNGR1 AR C Eþ [9]
AR C E  [10,11]
AD P Eþ [12]
AR P Eþ [13]
IFNGR2 AR C Eþ [14]
AR C E  [15]
AR P Eþ [16]
STAT1 AD P EþP  [17]
AD P EþB  This report
The 12 known genetic etiologies of MSMD, including the novel form of STAT1 deficiency
herein reported. Modes of inheritance are either autosomal dominant (AD) or autosomal
recessive (AR). The functional defects are either complete (C) or partial (P). The mutant
proteins are either expressed (Eþ) or not (E ), being not phosphorylated (P ) or not
binding DNA (B ) upon IFN stimulation.
DOI: 10.1371/journal.pgen.0020131.t001
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Synopsis
Mendelian susceptibility to mycobacterial disease is a rare syn-
drome. It is defined by the occurrence of severe disease caused by
low virulence mycobacteria in otherwise healthy individuals, in
whom antiviral immune response is not affected. Eleven known
genetic defects, affecting five genes, have been involved in this type
of deficient response to infection, involving immune-mediator
molecules IL12 and interferon gamma: IL12B, IL12RB1, IFNGR1,
IFNGR2, and STAT1. The signal transducer and activator of tran-
scription-1 (STAT1) amino acid change L706S was previously shown
to cause disease by impairing STAT1 phosphorylation. Here, we
report two new STAT1 mutations that impair STAT1 DNA-binding
activity. We show, by functional analysis of the three STAT1 mutant
alleles, that they are intrinsically deleterious for both interferon
gamma–induced antimycobacterial immunity, which is mediated
through gamma-activated factor and for interferon alpha–induced
antiviral immunity, which is mediated through interferon-stimulated
genes factor 3. Interestingly, the three alleles are dominant for
interferon gamma–induced gamma-activated factor–mediated anti-
mycobacterial immunity, but recessive for interferon alpha–induced
interferon-stimulated genes factor 3–mediated antiviral immunity at
the cellular and clinical levels. These two new STAT1 alleles, which
affect the binding of STAT1 to DNA, define distinct novel genetic
causes of Mendelian susceptibility to mycobacterial disease and
provide further insight into the molecular mechanism of disease.regions of the ﬁve genes known to be associated with MSMD
(IL12B, IL12RB1, IFNGR1, IFNGR2, and STAT1) were se-
quenced following ampliﬁcation of the corresponding cDNAs
from Epstein-Barr virus (EBV)–transformed B cells from the
patients. Mutations were found in STAT1 cDNAs, and were
conﬁrmed by sequencing products ampliﬁed from the
corresponding STAT1 genomic exons in EBV-transformed B
cells and fresh blood cells. No mutations were found in the
coding regions of the other four genes. A heterozygous
nucleotide substitution at position 958 (G!C) was found in
STAT1 exon 11 in P1, leading to a Glu!Gln substitution at
position 320 (E320Q). A heterozygous nucleotide substitution
at position 1389 (G!T) was found in exon 17 in P2, leading to
a Gln!His substitution at position 463 (Q463H). These
mutations were not found in 75 unrelated European control
individuals tested (150 chromosomes), suggesting they are not
merely irrelevant polymorphisms. Moreover, P19s mother
(A.III.2) had MSMD and was found to be heterozygous for the
E320Q allele. Analysis of genomic DNA extracted from biopsy
tissue taken from the deceased maternal grandfather of P1
(A.II.1), who had suffered from bona ﬁde tuberculosis, showed
that he too was heterozygous for the E320Q allele, providing
further evidence for dominant cosegregation of the STAT1
genotype and clinical phenotype. However, healthy relatives
of P2 (B.II.3 and B.III.3) were found to be heterozygous for
the Q463H mutation, suggesting that this allele (and possibly
E320Q), like the previously reported L706S STAT1 allele [17],
is associated with a partial form of STAT1 deﬁciency, with
low clinical penetrance.
Molecular Representation of STAT1 Mutants
According to the crystallographic structure of phosphory-
lated STAT1 dimers bound to DNA, the E320Q and Q463H
mutations affect residues from the DNA-binding domain of
STAT1 that are conserved in all known human STAT
molecules [32]. We therefore attempted to predict the effect
of these mutations on the binding of STAT1 homodimers to
their GAS target region. The 3D models of the mutants shed
light on the potential impact of these mutations on the
binding of STAT1 homodimers to their GAS target DNA
element (Figure 3A, 3B, and unpublished data). The acidic
E320 residue is located in a bulge at the very beginning of the
eight-strand b-barrel (Figure 3). It helps to stabilize the
structure through the salt bridge it forms with K344 and R346
on the adjacent antiparallel strand, which contains residues
in direct contact with DNA. Residue Q463 is directly involved
in DNA binding, forming a hydrogen bond with thymidine,
and coming into contact with the phosphate backbone of
DNA. It also forms hydrogen bonds with residues S459 and
N460, thereby stabilizing a loop that contacts DNA. These in
silico studies suggest that the E320Q and Q463H mutations in
STAT1 are deleterious, as they are expected to affect the GAS
DNA-binding activity of the corresponding mutant STAT1
Figure 2. Novel STAT1 Mutations in Two Kindreds
(A) STAT1 genotype and clinical phenotype of three kindreds. In kindred A, members I.1 and II.1 had tuberculosis, and III.2 and IV.1 (P1) had severe BCG
disease. In kindred B, members I.1 and III. 2 (P2) were infected with M. tuberculosis and M. avium, respectively. Kindred C has been described elsewhere;
II.2 (P3) developed disseminated BCG disease. Individuals with clinical disease caused by weakly virulent (BCG or M. avium) and more virulent (M.
tuberculosis) mycobacteria are indicated in black and gray, respectively, and healthy individuals are shown in white. The index cases are indicated with
an arrow. Genetically affected individuals (heterozygous for any of the three STAT1 mutations) with no clinical phenotype at the time of this study are
indicated by a vertical line. Known STAT1 genotypes (WT, E320Q, Q463H, L706S) are indicated under each individual, with a question mark indicating
unknown genotype.
(B) The human STAT1 coding region is shown, with its known pathogenic mutations. The coiled-coil domain (CC), DNA-binding domain (DNA-B), linker
domain (L), SH2 domain (SH2), tail segment domain (TS), and trans-activator domain (TA) are indicated, together with their amino-acid boundaries.
Tyrosine 701 (Y) is also indicated. Mutations in red are recessive mutations associated with complete STAT1 deficiency (due to a lack of STAT1
production), impaired IFNG-induced GAF activation and IFNA-induced ISGF3 activation, and a syndrome of predisposition to mycobacterial and severe
viral disease in homozygous individuals. Mutations in green are associated, in heterozygous individuals, with partial STAT1 deficiency (normal STAT1
expression), impaired IFNG-induced GAS-binding activity but normal IFNA-induced ISRE-binding activity, and MSMD (predisposition to mycobacterial
but not viral disease). Mutations reported for the first time in this study are indicated in italics.
DOI: 10.1371/journal.pgen.0020131.g002
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STAT1 Mutationsproteins either directly or indirectly. They also suggest that
the E320Q allele may be less severe than the Q463H allele. In
contrast, residue L706 is located in the C-terminal tail
segment (residues 701–708), which is involved in STAT1
activation by phosphorylation of Y701 and STAT1 homo-
dimerization. Residue L706 from one STAT1 molecule packs
against a hydrophobic pocket formed by the side-chains of
L706, I707, A641, and V642 from the other STAT1 molecule.
The L706S mutation might therefore be expected to impair
the Y701 phosphorylation and dimerization of STAT1.
Normal Activation of STAT1 in Heterozygous Cells from
Patients
We assessed STAT1 production in EBV-transformed B cells
from a healthy control individual (C), the patients under
study (P1 and P2), a previously reported patient with partial
STAT1 deﬁciency carrying the heterozygous L706S STAT1
mutation (P3) [17], and a patient with complete STAT1
deﬁciency carrying the homozygous 1758_1759delAG STAT1
frameshift deletion (P4) [36] by Western blotting with a
speciﬁc antibody (Figure 4A). Cells from P1, P2, and P3
produced similar amounts of STAT1 protein to control cells
(C), whereas STAT1 was absent in cells from P4 (Figure 4A
and Table 2). Cells from P3 contained about half the normal
amount of Y701-phosphorylated STAT1 following treatment
with either type of IFN (Figure 4A), as previously described
[17]. In contrast, cells from P1 and P2 had normal levels of
Y701-phosphorylated STAT1 following treatment with either
type of IFN (Figure 4A and Table 2). We then investigated the
nuclear translocation of STAT1 upon IFN stimulation in
simian virus 40 (SV40)–transformed ﬁbroblasts from a
healthy control (C), patients P1, P2, and P3, the STAT1-
deﬁcient ﬁbrosarcoma cell line U3C, and its parental cell line
2C4 by immunoﬂuorescence staining with a speciﬁc antibody.
STAT1 nuclear accumulation in response to both IFNA and
IFNG was normal in ﬁbroblasts from P1 and P2, whereas it
was, as expected, impaired in cells from P3 (Figure 4B and
Table 2) [17]. No staining was observed in U3C STAT1-
deﬁcient ﬁbroblasts incubated with a STAT1-speciﬁc anti-
body, or in any other ﬁbroblast line incubated with an
isotypic control antibody (unpublished data). Staining with a
STAT2-speciﬁc antibody indicated that the STAT1-contain-
ing complexes accumulating in the nucleus in response to
IFNA consisted, at least partly, of ISGF3 ([17,36] and
unpublished data). Thus, the E320Q and Q463H STAT1
mutations do not seem to impair the production of STAT1,
its phosphorylation at Y701 (activation), or its accumulation
in the nucleus following the stimulation of heterozygous cells
with IFNA and IFNG.
Impaired STAT1 DNA-Binding Activity in Heterozygous
Cells from the Patients
We further investigated the impact of the mutations by
assessing the DNA-binding activity of GAF and ISGF3 in EBV-
transformed B cells stimulated with IFNG and IFNA by
electrophoretic mobility shift assay (EMSA; Figure 4C–4E).
Upon IFNG stimulation, cells from P1, P2, and P3 showed
impaired GAS-binding activity (Figure 4C, 4D, and Table 2).
The GAS-binding activity detected in cells from P2 and P3
was found to be about 25% of normal levels following
treatment with 10
5 IU/ml IFNG (mean of 4 experiments, 6
5%) [17] (Figure 4D). The GAS-binding activity detected in
cells from P1 was found to be mildly, but reproducibly higher,
at about 33% (mean of 6 experiments, 6 9%) (Figure 4D).
Seventeen controls were tested and variation was found to be
less than 20% of the mean value (unpublished data). The
GAS-binding activity of P1, P2, and P3 on IFNA stimulation
was also found to be impaired, indicating that the phenotype
observed was strictly STAT1 dependent and independent of
the amount of phosphorylated STAT1 (Figure S1A). Upon
IFNA stimulation, P1, P2, and P3 presented normal IFN-
stimulated response element (ISRE)–binding activity [17]
(Figure 4E and Table 2). The addition of unlabeled probes
to the EMSA indicated that the signals detected were GAS
and ISRE speciﬁc (unpublished data). Supershift experiments
with STAT1-, STAT2-, STAT3-, and ISGF3G-speciﬁc anti-
bodies indicated that GAS- and ISRE-binding activities were
mediated by GAF and ISGF3, respectively (unpublished data).
Finally, we observed strict cosegregation of the STAT1
genotype and cellular phenotype, with impaired IFNG-
induced GAS-binding activity in all individuals heterozygous
for a mutant STAT1 allele, and in none of their wild-type
Figure 3. Molecular Representation of STAT1 Mutants
(A) Ribbon representation of the WT STAT1 homodimer complexed with
DNA. Secondary structure elements representing the b strands are
shown in cyan, and the helices are shown in blue-magenta. Atoms of
residues in mutated positions L706, E320, and Q463 (indicated by arrows)
are shown in space-filling models. Atoms are shown in red (for oxygen),
blue (for nitrogen), and gray (for carbon).
(B) Magnified focus on the region containing the three mutated residues.
DOI: 10.1371/journal.pgen.0020131.g003
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STAT1 Mutationshomozygous relatives (data not shown). These data suggest
that the E320Q and Q463H STAT1 alleles are pathogenic and
associated with dominant and partial STAT1 deﬁciency, and
with MSMD of low clinical penetrance, due to impaired GAS
binding by nuclear phophorylated STAT1 homodimers in
response to IFNG. We cannot discriminate whether mutated
proteins bind with less or no afﬁnity or bind with a greater
off rate.
Normal Activation of STAT1 Mutants in Stable
Transfectants
Experiments conducted in heterozygous cells do not allow
precise dissection of the molecular mechanisms involved. We
therefore cotransfected the STAT1-deﬁcient U3C ﬁbroblast
line with a zeocin-resistance vector and a vector carrying
mock or STAT1 alleles (wild-type [WT], E320Q, Q463H, and
L706S), and selected stable clones on the basis of zeocin
Figure 4. Normal Activation but Impaired DNA-Binding Activity of STAT1 in Heterozygous Cells from Patients
(A) Western blot of total protein extracts (100 lg) from EBV-transformed B cells derived from a healthy control (C), three patients under study (P1, P2,
P3), and a patient with recessive complete STAT1 deficiency (P4) homozygous for the 1758_1759delAG mutation, probed with specific antibodies
against phosphorylated-Tyr-701-STAT1, STAT1, and STAT3. EBV-transformed B cells were not stimulated (NS) or were stimulated with IFNA or IFNG (10
5
IU/ml) for 30 min.
(B) Immunofluorescence staining with a STAT1-specific antibody of skin-derived SV40-transformed fibroblasts from a healthy control (C) and three
patients under study (P1, P2, P3). Fibroblasts were not stimulated (NS) or were stimulated with IFNA or IFNG (10
5 IU/ml) for 30 min.
(C and E) EMSA of nuclear extracts (5 lg) from EBV-transformed B cells derived from a healthy control (C), three patients under study (P1, P2, P3), and
the patient with complete STAT1 deficiency (P4). EBV-transformed B cells were not stimulated (NS) or were stimulated for 30 min with 10
3 and 10
5 IU/ml
of IFNG (C) and IFNA (E), respectively. Radiolabeled GAS (C) or ISRE (E) probes were used.
(D) Quantification of four to six independent experiments by PhosphoImager SI (Molecular Dynamics, Piscataway, New Jersey, United States) using the
GAS probe in response to 10
5 IU/ml of IFNG is also presented. The mean, minimum, and maximum values are expressed with respect to the positive
control response (100%).
For (A–C) and (E), one experiment representative of three to five independent experiments is shown.
DOI: 10.1371/journal.pgen.0020131.g004
Table 2. STAT1 Genotypes and Associated Cellular Phenotypes
STAT1
Expression
P-STAT1 upon
IFN Stimulation
Translocation upon
IFN Stimulation
IFNG
GAF
IFNA
ISGF-3
Patient (STAT1 Genotype) P1 (E320Q/WT) N N N P (D) N (R)
P2 (Q463H/WT) N N N P (D) N (R)
P3 (L706S/WT) N P P P (D) N (R)
STAT1-Mutated Clones E320Q N N N P (–) P (–)
Q463H N N N C (–) C (–)
L706S N C C C (–) C (–)
STAT1 genotypes and the corresponding cellular phenotypes in cells from the heterozygous patients and in STAT1-deficient cells stably transfected with the respective mutant STAT1
alleles.
N, normal result; P, partial defect; C, complete defect, compared with a positive control; D, dominant; R, recessive; (–), deleterious (a- or hypomorphic).
DOI: 10.1371/journal.pgen.0020131.t002
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STAT1 Mutationsresistance. We assessed STAT1 production in the various cell
lines by Western blotting with a speciﬁc antibody (Figure 5A).
The WT, E320Q, Q463H, and L706S alleles were overex-
pressed with respect to the control cell line (2C4). No STAT1
was detected in parental U3C cells or stable clones trans-
fected with a mock vector. STAT1 was normally phosphory-
lated at Y701 upon stimulation with either IFNA or IFNG in
the WT, E320Q, and Q463H cell lines, but not in the L706S
cell line (Figure 5A and Table 2). We then assessed the nuclear
accumulation of STAT1 upon stimulation with IFNA and
IFNG by immunoﬂuorescence assays with a speciﬁc antibody
(Figure 5B). Nuclear accumulation was observed for WT,
E320Q, and Q463H STAT1, but not for L706S STAT1
molecules, in response to both IFNG and IFNA (Figure 5B
and Table 2). No ﬂuorescence was observed in U3C parental
cells or stable clones transfected with a mock vector or using
an isotypic control antibody (unpublished data). These data
conﬁrm that the STAT1 L706S mutation is associated with a
complete lack of Y701 phosphorylation and subsequent
nuclear translocation of STAT1 upon stimulation with IFNA
and IFNG [17]. Our ﬁndings also indicate that the STAT1
E320Q and Q463H alleles encode proteins that are normally
phosphorylated at Y701 and translocated upon stimulation
with either IFNA or IFNG [31].
Impaired DNA-Binding Activity of STAT1 Mutants in Stable
Transfectants
We then assessed the impact of STAT1 mutations on DNA-
binding activity in EMSA. In response to even high doses of
IFNG (10
5 IU/ml), no GAS binding was detected with the
Q463H and L706S STAT1 alleles, despite the use of several
GAS probes (FCGR1, M67, and IRF1) (Figure 6A; unpublished
data and Table 2). E320Q cell lines (producing similar
amounts of STAT1 to the WT; Figure 6A and Table 2) were
found to have impaired, but not abolished GAS-binding
activity at various concentrations of IFNG (Figure 6A and 6B)
(37%, mean of ﬁve experiments, 67%). Similar results were
obtained upon IFNA stimulation, indicating the phenotype
observed was strictly STAT1 dependent and independent of
the amount of phosphorylated STAT1 (Figure S1B and S1C).
In addition, Q463H and L706S were found to be associated
with a lack of ISRE-binding activity on stimulation with even
high doses of IFNA (10
5 IU/ml) (Figure 6C and Table 2),
whereas the E320Q allele displayed only mildly impaired
binding (90%, mean of three experiments, 6 17%) at the two
highest concentrations of IFNA (Figure 6D, 6E, and Table 2).
This reﬂects the known involvement of STAT1 with ISGF3G in
ISGF3 binding to ISRE [35], and indicates that Q463H and, to
a lesser extent, E320Q, impair this process. The GAS- and
ISRE-binding activities of WT and E320Q cells were shown to
involve GAF and ISGF3, respectively, in competition experi-
ments with unlabeled probe and supershift experiments
(unpublished data). Thus, the L706S STAT1 allele is therefore
null for the DNA-binding activity of both GAF (to GAS
elements) and ISGF3 (to ISRE elements), as previously shown
in transient transfectants [17]. This defect is due to impaired
Y701 phosphorylation and nuclear accumulation. The Q463H
allele is also null for both cellular phenotypes, but the
underlying mechanism is different, involving impaired DNA
binding by nuclear STAT1-containing complexes. The E320Q
allele acts by a similar mechanism, affecting DNA binding, but
has a milder impact, being markedly hypomorphic for GAS-
binding activity and barely hypomorphic for ISRE-binding
activity. We cannot determine whether mutated proteins bind
with less or no afﬁnity or bind with a greater off rate.
Impact of STAT1 Mutations on Transcription
We validated our ﬁndings by assessing the impact of STAT1
mutations on transcription by Northern blotting and relative
real-time RT-PCR to determine the amount of mRNA for
various IFNG- and IFNA-inducible genes [36] in EBV-trans-
formed B cells from the patients (Figure 7A and 7B). Target
genes ISG15 (the promoter of which was used for EMSA),
MX1, and IRF1 (the promoter of which was used for EMSA)
were induced following stimulation with IFNA and IFNG, as
appropriate, in control cells, but not in cells from a patient
lacking STAT1 (P5, homozygous for the 1928insA STAT1
allele, which encodes no detectable protein) [37]. Cells from
heterozygous patients P1, P2, and P3 showed no impairment
of the induction of STAT1-dependent target genes in
response to IFNG and IFNA. This ﬁnding conﬁrms that these
patients suffer from partial, as opposed to complete, STAT1
deﬁciency, with a mild effect on GAF-mediated IFNG
responses and not on ISGF3-mediated IFNA responses
[17,36]. We then assessed the induction of the same target
genes in stably transfected ﬁbroblasts (Figure 7A and 7B).
Target genes were induced in control cells and in stable
clones transfected with WT STAT1 allele, but not in STAT1-
deﬁcient U3C and in stable clones transfected with a mock
vector. They were not induced in either L706S or Q463H
transfectants. This conﬁrms that the L706S and Q463H alleles
Figure 5. Normal Activation of STAT1 Mutants in Stable Transfectants
(A) Western blot of total protein extracts (100 lg) from a parental
fibrosarcoma cell line (2C4) and STAT1-deficient U3C fibrosarcoma cell
clones, untransfected (U3C) or stably cotransfected with a zeocin-
resistance vector and a vector containing a mock (pmock), WT, E320Q,
Q463H, or L706S STAT1 allele, with antibodies specific for phosphory-
lated-Tyr-701-STAT1, STAT1, and STAT3. The cells were not stimulated
(NS) or were stimulated for 30 min with 10
5 IU/ml IFNA or IFNG.
(B) Immunofluorescence staining, with a STAT1-specific antibody, of
STAT1-deficient U3C fibrosarcoma cell clones, stably cotransfected with a
zeocin-resistance vector and a vector containing a WT, E320Q, Q463H, or
L706S STAT1 allele. The cells were not stimulated (NS) or were stimulated
with IFNA or IFNG (10
5 IU/ml) for 30 min.
For (A) and (B), one experiment representative of three independent
experiments is shown.
DOI: 10.1371/journal.pgen.0020131.g005
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STAT1 Mutationsare loss-of-function alleles for IFNG-driven GAF and IFNA-
driven ISGF3 activation. In contrast, the induction of ISG15
and MX1 were impaired, but not abolished in cells expressing
the E320Q hypomorphic allele. The induction of IRF1 was
abolished. These data conﬁrm that (1) the three mutant
STAT1 alleles are associated with partial, as opposed to
complete STAT1 deﬁciency for GAF-dependent IFNG-indu-
cible genes in heterozygous patients; and (2) the L706S and
Q463H alleles are intrinsically loss-of-function, whereas the
E320Q allele is hypomorphic for both GAF-dependent IFNG-
inducible and ISGF3-dependent IFNA-inducible gene tran-
scription.
Mechanism of Dominance of the STAT1 Alleles for GAS-
Binding Activity
We investigated the molecular mechanisms of dominance
of E320Q, Q463H, and L706S STAT1 alleles by studying EBV-
transformed B cells from P49s father (þ/ ) (heterozygous for
the 1758_1759delAG STAT1 allele encoding no detectable
STAT1 [36]). These cells produced half the amount of STAT1
detected in six control cell lines (Figure 8A; unpublished
data) but responded normally to IFNG in terms of GAS-
binding activity (Figure 8B). This clearly demonstrates that
STAT1 mutant alleles cannot be dominant due to haploin-
sufﬁciency, implying the involvement of a negative-domi-
Figure 6. Impaired DNA-Binding Activity of STAT1 Mutants in Stable Transfectants
(A–D) EMSA of nuclear extracts (5 lg [A and B]; 30 lg [C and D]) from a parental fibrosarcoma cell line (2C4) and STAT1-deficient U3C fibrosarcoma cell
clones, untransfected (U3C) or stably cotransfected with a zeocin-resistance vector and a vector containing a mock (pmock), WT, E320Q, Q463H, or
L706S STAT1 allele. The cells were not stimulated (NS) or were stimulated for 30 min with the indicated doses of IFNG (A and B) or IFNA (C and D). We
used the radiolabeled GAS probe FCGR1 (A and B) or an ISRE probe (C and D). For (A–D), one experiment representative of three to five independent
experiments is shown.
(E) Quantification of three independent experiments by PhosphoImager SI (Molecular Dynamics), using the ISRE probe, in response to 10
4 and 10
5 IU/ml
IFNA is also presented. The mean, minimum, and maximum values are expressed with respect to the WT stable transfectant clone response (100%).
DOI: 10.1371/journal.pgen.0020131.g006
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STAT1 Mutationsnance mechanism for the three mutant STAT1 alleles studied
here. We previously dissected the molecular mechanism
involved in the loss-of-function and dominance associated
with the L706S allele [17]. The docking site of unphosphory-
lated STAT1 on IFNGR1 has been shown to be created by the
phosphorylation of Tyr 440 upon IFNG stimulation [30]. We
further dissected this molecular mechanism underlying the
negative dominance of the L706S allele, using biotinylated
peptides corresponding to an intracellular segment of
IFNGR1, unphosphorylated or phosphorylated at Tyr 440,
or an irrelevant phosphorylated peptide. We incubated the
peptides with whole-cell protein extracts from WT, L706S,
and mock stable transfectant cell lines. Streptavidin immu-
noprecipitates were analyzed by Western blotting with a
STAT1-speciﬁc antibody (Figure 8C). We found that the
phosphorylated IFNGR1 peptide, unlike the other two
peptides, interacted strongly with WT and L706S STAT1
molecules, indicating that the L706S mutation does not
impair the recruitment of STAT1 by phosphorylated IFNGR1
upon IFNG stimulation. The loss-of-phosphorylation associ-
ated with the L706S allele is therefore necessary and
sufﬁcient to account for the associated loss-of-function and
the dominance of this allele. The loss-of-function Q463H
allele, acting by a different mechanism, is also dominant for
GAF activation in response to IFNG: only one in four
combinations of STAT1-activated phosphodimers binds GAS
correctly in the Q463H/WT cells from P2 (25% of normal
levels). Interestingly, E320Q/WT cells from P1 had a higher
level of IFNG-induced GAS-binding activity (33% of normal
levels). The E320Q allele is dominant, for the same reasons as
Q463H, but gives stronger responses to IFNG because it is
hypomorphic (some E320Q-containing GAF molecules do
bind GAS; Figure 6A and 6B).
Mechanism of Recessivity of STAT1 Alleles for ISRE-Binding
Activity
We investigated the molecular mechanisms underlying the
recessivity of the three deleterious mutations E320Q, Q463H,
and L706S for ISGF3 binding to ISRE. We investigated P49s
father, who produces half as much STAT1 protein as the
control (Figure 8A). His EBV-transformed B cells activated
normal amounts of ISRE-binding ISGF3 proteins upon
stimulation with IFNA (Figure 8D). Thus, deleterious STAT1
alleles, whether affecting Y701 phosphorylation or DNA
binding, cannot be haploinsufﬁcient for ISGF3 binding to
ISRE. Moreover, as ISGF3 complexes contain a single STAT1
molecule bound to STAT2 and ISGF3G (unlike GAF, which
contains two STAT1 molecules), a mechanism involving the
negative dominance of mutant STAT1 alleles would require
mutant STAT1 proteins to bind preferentially to STAT2 and
ISGF3G, increasing the proportion of inactive ISGF3 com-
plexes. We thus investigated whether the E320Q, Q463H, and
L706S STAT1 proteins could interact with nonphosphory-
lated STAT2 in unstimulated cells (preassociation [29,38,39]),
and with tyrosine-phosphorylated STAT2 upon IFNA stim-
ulation [40]. We subjected stably transfected ﬁbroblast cell
Figure 7. Impact of STAT1 Mutations on Transcription
(A) Levels of mRNA corresponding to STAT1, IFNG- and/or IFNA-inducible genes (IRF1 and ISG15) and GADP in EBV-transformed B cells from a control (C),
the three affected individuals (P1, P2, and P3) and a STAT1-deficient individual (P4), or in the 2C4 parental fibrosarcoma cell line, STAT1-deficient U3C
cell line, and U3C cells stably transfected with a mock (pmock), WT, E320Q, Q463H, or L706S STAT1 allele, either not stimulated (NS), or stimulated for 2 h
with 10
3 of IFNG or 10
4 of IFNA for EBV-transformed B cells and 10
5 IU/ml of IFNG or IFNA for fibroblasts, as detected by Northern blotting.
(B) Relative real-time PCR of IRF1, ISG15, and MX1, and cDNAs from EBV-transformed B cells derived from a healthy control (C), three patients under
study (P1, P2, P3), and a patient with recessive complete STAT1 deficiency (P5) homozygous for the 1928insA STAT1 mutation or from parental
fibrosarcoma cell line (2C4) and STAT1-deficient U3C fibrosarcoma cell clones, untransfected (U3C) or stably cotransfected with a zeocin-resistance
vector and a vector containing a mock, WT, E320Q, Q463H, or L706S STAT1 allele stimulated or not stimulated with 10
5 IU/ml of IFNG or IFNA for 1 h and
2 h for EBV-transformed B cells and fibroblasts, respectively, for IRF1, and for 6 h for both cellular types for ISG15 and MX1. Means values of duplicates of
one experiment are shown with their respective standard variations.
DOI: 10.1371/journal.pgen.0020131.g007
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STAT1 Mutationslines, left unstimulated or stimulated with IFNA, to immu-
noprecipitation with a STAT1-speciﬁc antibody, followed by
Western blotting with speciﬁc antibodies directed against
tyrosine-phosphorylated STAT2, STAT2, tyrosine-phos-
phorylated STAT1, and STAT1 (Figure 8E). Similar levels of
preassociation between nonphosphorylated WT, E320Q,
Q463H, and L706S STAT1 molecules and nonphosphorylated
STAT2 were observed in resting cells. Upon IFNA stimula-
tion, phosphorylated WT, E320Q, and Q463H STAT1
molecules interacted equally strongly with phosphorylated
STAT2, whereas L706S displayed no high-afﬁnity interaction
with phosphorylated STAT2. This may reﬂect the docu-
mented lack of L706S phosphorylation at Y701, or the
predicted impairment of Stat phosphodimer formation due
to replacement of the key residue L706 [32], or both. Thus, (1)
nonphosphorylated L706S STAT1 molecules are not associ-
ated with phosphorylated STAT2 upon IFNA stimulation,
revealing a second impact of L706S, in addition to the loss of
Y701 phosphorylation, accounting in part for the recessive
nature of this mutation for ISGF3 activation; and (2) the
E320Q and Q463H STAT1 mutants are normally recruited by
phosphorylated STAT2, with which they form phosphory-
lated heterodimers. All three alleles are therefore recessive
because no more than half of the ISGF3 complexes (none in
the case of L706S) contain a mutant STAT1 molecule in
heterozygous cells, and there is no haploinsufﬁciency.
Impact of Mutant STAT1 Alleles on IFNG-Mediated
Immunity
We evaluated the physiological relevance of our studies by
assessing the impact of the E320Q, Q463H, and L706S STAT1
alleles on IFNG-dependent immunity in a whole-blood assay
by studying the late induction of IL12p70 in response to live
bacille Calmette-Gue ´rin (BCG), or live BCG plus IFNG, and
the induction of IFNG production in response to live BCG, or
live BCG plus IL12, in the patients [41] (Figure 9A). We
studied blood cells from P19s mother, rather than from P1,
for convenience. These cells had the same STAT1 genotype
and cellular phenotype as the cells of P1 in terms of the
response to IFNG of EBV-transformed B cells. Accordingly,
the response to BCG plus IL12 was normal in terms of IFNG
production. Moreover, P19s mother, P2, and P3 presented a
complete lack of induction of IL12p70 in response to BCG
plus IFNG (Figure 9A), as in all patients with complete or
partial IFNGR1, and IFNGR2 deﬁciencies [41]. IL12 produc-
tion in response to LPS was studied as a control and was
found to be normal in P19s mother and P3. These
immunological results, obtained with fresh blood cells,
correlate with biochemical assays performed on the patient’s
EBV-transformed B cells. This cellular phenotype accounts
for the immunological phenotype of impairment of the IL12–
IFNG circuit upon stimulation of the blood cells with
mycobacteria and IFNG ex vivo. This immunological pheno-
type is, in turn, correlated with the clinical phenotype of
impaired antimycobacterial immunity in vivo.
Figure 8. Mechanism of Dominance of the STAT1 Alleles for GAS-Binding
Activity and of Recessivity of the STAT1 Alleles for ISRE-Binding Activity
(A) Western blot of total protein extracts (100 lg) from unstimulated
EBV-transformed B-cell lines from a healthy control (þ/þ), P49s father (þ/
 ) (heterozygous for the loss-of-expression, loss-of-function STAT1
1758_1759delAG allele), and P5 ( / ) (homozygous for the loss-of-
expression, loss-of-function STAT1 1928insA allele), using antibodies
specific for STAT1 and STAT3.
(B) EMSA of nuclear extracts (5 lg) from EBV-transformed B cells derived
from a healthy control (þ/þ), P5 ( / ) (homozygous for the loss-of-
expression, loss-of-function STAT1 1928insA allele), and P49s father (þ/ )
(heterozygous for the loss-of-expression, loss-of-function STAT1
1758_1759delAG allele). EBV-transformed B cells were not stimulated
(NS) or were stimulated for 30 min with 10
5 IU/ml IFNG. A radiolabeled
GAS (FCGR1) probe was used.
(C) (a) Whole-cell extracts of 10
7 STAT1-deficient U3C fibrosarcoma cell
clones stably cotransfected with a zeocin-resistance vector and a vector
containing a mock (pmock), WT, or L706S STAT1 allele were subjected to
immunoprecipitation with the following biotinylated peptides:
TSFGYDKPHVLV (1), corresponding to the intracellular part of IFNGR1
around the unphosphorylated Tyr-440 residue (Y); TSFG(pTyr)DKPHVLV
(2), corresponding to the intracellular part of IFNGR1 around the
phosphorylated Tyr-440 residue (pTyr); and SLIG(pTyr)RPTEDSK (3),
corresponding to an irrelevant peptide similar to peptide 2. (b) 20 lL
of each extract was taken before immunoprecipitation, and Western
blotting was performed with STAT1- and STAT3-specific antibodies.
(D) EMSA of nuclear extracts (5 lg) from EBV-transformed B cells derived
from a healthy control (C), P49s father (þ/ ) (heterozygous for the loss-of-
expression, loss-of-function STAT1 1758_1759delAG allele) and P5 ( / )
(homozygous for the loss-of-expression, loss-of-function STAT1 1928insA
allele). EBV-transformed B cells were not stimulated (NS) or were
stimulated for 30 min with 10
5 IU/ml of IFNA. A radiolabeled ISRE probe
was used.
(E) Immunoprecipitation with a STAT1-specific antibody, followed by
Western blotting with Tyr701-phospho-STAT1–specific, Tyr690-phospho-
STAT2–specific, STAT1-specific, and STAT2-specific antibodies, of total
protein extracts (1 mg) from a parental fibrosarcoma cell line (2C4), a
STAT2-deficient U6A fibrosarcoma cell line, and STAT1-deficient U3C
fibrosarcoma cell clones, untransfected (U3C) or stably cotransfected
with a zeocin-resistance vector and a vector containing a mock, WT,
E320Q, Q463H, or L706S STAT1 allele. The cells were not stimulated (NS)
or were stimulated for 30 min with 10
5 IU/ml IFNA.
For (B–E), one experiment representative of two independent experi-
ments is shown.
DOI: 10.1371/journal.pgen.0020131.g008
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STAT1 MutationsImpact of Mutant STAT1 Alleles on IFNA-Mediated
Immunity
We then evaluated the physiological relevance of our
studies by assessing the impact of the E320Q, Q463H, and
L706S STAT1 alleles on IFNA-dependent immunity. We
evaluated the response to IFNA of SV40-transformed
ﬁbroblasts from the patients, in terms of the control of
herpes simplex virus (HSV) and vesicular stomatitis virus
(VSV) infections (Figure 9B) [36,37]. Heterozygous cells from
the patients controlled the growth of HSV and VSV normally
in response to IFNA, consistent with the E320Q, Q463H, and
L706S alleles being recessive for ISGF3 activation. We
subjected stably transfected ﬁbroblast cell lines to the same
assay, and in contrast, cell lines expressing only Q463H or
L706S controlled the growth of neither HSV nor VSV in
response to IFNA, consistent with these alleles being null for
ISGF3 activation (Figure 9B). The E320Q cell line presented
no detectable defect in the control of HSV, but control of the
Figure 9. Impact of Mutant STAT1 Alleles on IFNG- and IFNA-Mediated Immunity
(A) Cytokine production in the supernatant of whole blood from healthy controls (C) and patients (P19s mother, P2, and P3) and their respective ‘‘travel’’
control, not stimulated (NS) or stimulated for 72 h with live BCG alone or BCG plus IL12 or IFNG. The levels of IFNG and IL12 in the supernatant were
determined by enzyme-linked immunosorbent assay. One experiment representative of two independent experiments is shown.
(B) Skin-derived SV40-transformed fibroblasts from a healthy control (C), the three patients under study (P1, P2, P3), a parental fibrosarcoma cell line
(2C4), STAT1-deficient U3C fibrosarcoma cell line (U3C), and U3C clones stably transfected with a mock (pmock), WT, E320Q, Q463H, or L706S STAT1
alleles, were infected with HSV-1 or VSV, with or without priorstimulation with IFNA (10
5 IU/ml) for 24 h. Viral titers were determined after 48 h of
infection. Five independent experiments are shown for the patient’s cells and three independent experiments are shown for sarcoma fibroblasts. Each
assay is symbolized by a different character.
DOI: 10.1371/journal.pgen.0020131.g009
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STAT1 Mutationsmore virulent VSV was clearly impaired. Similar data were
reproducibly obtained with several concentrations of IFNA
(data not shown). The deleterious impact of the hypomorphic
E320Q allele therefore impaired, but did not completely
abolish the response to IFNA, even at high doses (10
5 IU/ml).
These functional results are therefore correlated with the
ISRE-binding and ISGF3 transcriptional phenotypes. Hetero-
zygous cell lines displayed normal ISRE-binding activity of
ISGF3 and the normal induction of target genes in response
to IFNA. This biochemical phenotype accounts for the
immunological phenotype of normal control of HSV and
VSV growth in vitro. This immunological phenotype is
correlated with a clinical phenotype of normal resistance to
most viruses in vivo [17] (case reports). Thus, the deleterious
E320Q, Q463H, and L706S mutations are dominant for GAS-
binding and GAF transcriptional activity and antimycobacte-
rial immunity and recessive for ISRE-binding and ISGF3
transcriptional activity and antiviral immunity.
Discussion
We describe here a novel form of partial STAT1 deﬁciency,
the 12th genetic etiology of MSMD to be identiﬁed and the
second form of STAT1 deﬁciency shown to be associated with
this syndrome [14,17]. The previously described L706S STAT1
mutation in two kindreds leads to a defect in STAT1
phosphorylation at Y701 [17]. The E320Q and Q463H alleles
result in impaired GAS binding by normally phosphorylated
nuclear STAT1 homodimers. This ﬁnding has important
clinical implications, because the screening of patients with
MSMD by the detection of phosphorylated STAT1 in IFNG-
stimulated blood cells would not detect this new form of
STAT1 deﬁciency [42]. Measuring the induction of IL12 in
response to IFNG is more appropriate as a ﬁrst diagnostic
step [41]. The clinical phenotype of patients with partial
STAT1 deﬁciency is mild and resembles that of patients with
partial IFNGR1 [19] and IFNGR2 [16] deﬁciencies. The
penetrance of partial STAT1 deﬁciency is low, as only ﬁve
of ten heterozygous patients from four kindreds [17] had
case-deﬁnition infectious diseases caused by poorly virulent
mycobacteria, reﬂecting the complex interplay between host
and environmental factors in the course of infections [43,44].
Interestingly, one deceased patient (A.II.1) heterozygous for
the E320Q allele suffered from bona ﬁde tuberculosis. Two
deceased relatives (A.I.1 and B.I.1) also had tuberculosis,
possibly due to heterozygosity for the deleterious STAT1
alleles. This ﬁnding is reminiscent of our observation of
patients with IL12RB1 deﬁciency presenting with tuber-
culosis as their sole clinical phenotype [44,45].
The three mutant alleles are intrinsically deleterious for
both IFNG-induced GAF-mediated and IFNA-induced ISGF3-
mediated cellular activations, as shown in STAT1-deﬁcient
cells transfected with the corresponding alleles (Table 2 and
Figure 1). There is no haploinsufﬁciency of STAT1 for IFNG-
induced GAF activation, and these three alleles are dominant
for this pathway by negative interaction. L706S STAT1 is
recruited to IFNGR1 but is not phosphorylated in response to
IFNG. Consistent with the ordered, afﬁnity-driven IFNG
signaling process, only one (WT/WT) of the four possible
STAT1 (WT/WT, WT/L706S, L706S/WT, L706S/L706S) combi-
nations therefore forms phosphodimers in heterozygous cells.
Whereas L706S exerts its negative effect in the cytosol, the
other two mutations, E320Q and Q463H STAT1, exert their
negative effects in the nucleus. Only one (WT/WT) of the four
possible STAT1 combinations forms phosphodimers binding
GAS elements with normal afﬁnity. In contrast, all three
alleles are recessive for the IFNA-induced ISGF3-mediated
signaling pathway. There is neither haploinsufﬁciency nor
negative interaction. The lack of negative dominance, in
particular, is accounted for by the three STAT1 mutant
proteins being no better recruited than WT STAT1 proteins
to phospho-STAT2 and the IFNAR. Indeed, L706S STAT1
may not be recruited at all to IFNAR-bound phospho-STAT2.
Altogether, the STAT1 alleles studied here are dominant for
IFNG-induced GAF-mediated signaling and recessive for
IFNA-induced ISGF3-mediated signaling.
The three STAT1 mutations are deleterious via different
mechanisms, and they affect both cellular and clinical
phenotypes, with a well-deﬁned causal relationship between
cellular defects and clinical diseases.Impaired IFNG-mediated
immunity is associated with mycobacterial diseases, whereas
impaired IFNA-mediated immunity is associated with viral
diseases. It is widely accepted that the deﬁnition of candidate
genes should take into account the observation that mutations
in genes involved in multiple pathways in vitro can have an
impact on only a few biochemical pathways in vivo, reﬂecting
variable redundancy of the gene product. For example,
complete STAT1 deﬁciency principally affects IFNA and
IFNG responses in mice [46,47] and humans [36,37] in vivo, but
STAT1 is involved, albeit in a redundant manner, in many
other pathways studied in vitro. Our study shows that the
deﬁnition of candidate genes, for both cellular and clinical
phenotypes, should also take into account the possibility that
the impact of the gene may depend on whether the organism
studied is heterozygous or homozygous for the mutation. As a
proof of principle, the three STAT1 alleles profoundly affect
IFNG-mediated immune responses to mycobacteria, but not
IFNA-mediated immune responses to viruses, in heterozygous
cells and patients, whereas they would affect both responses in
homozygous cells and patients [36,37].
Materials and Methods
Patients. P1 was born in Germany to unrelated German parents
(Figure 2). He was vaccinated with BCG at birth. During the ﬁrst year
of his life, he developed disseminated BCG disease (BCG-osis) with
fever, tuberculoid granulomatous inﬂammation, several small spots of
osteolysis in his shoulder blade (close to the point at which the
vaccine was administered), and a slightly enlarged spleen and
enlarged lymph nodes in the lower abdomen. All conventional
immunological assays (B cells, T cells, phagocytic respiratory burst)
were normal. The patient was treated with antibiotics (isoniazid and
rifampicin) for 7 mo and recovered. He was healthy at the age of 8 y
as of June 2005. His mother developed local BCG disease (BCG-itis)
after BCG vaccination at 14 y of age. She was healthy at the age of 38 y
as of June 2005. P19s maternal grandfather developed disseminated
tuberculosis at the age of 16 y. At the age of 32 y, he developed a
severe skin disease with deep lupus vulgaris-like ulcers that destroyed
part of his nose. He died at the age of 49 y from liver cancer due to
cirrhosis of unknown origin. P19s mother’s paternal grandfather died
at the age of 38 y from tuberculosis. P1 had high titers of serum
antibodies against mumps virus, varicella zoster virus, EBV, measles
virus, rubella virus, inﬂuenza A virus, adenovirus, and respiratory
syncytial virus. His mother had high titers of serum antibodies against
hepatitis A virus, hepatitis B virus, varicella zoster virus, EBV, mumps
virus, parvovirus B19, paranﬂuenza virus, adenovirus, respiratory
syncytial virus, and enterovirus. The medical history of P2, also born
to unrelated German parents in Germany, has been described
elsewhere [48]. Brieﬂy, he developed pulmonary M. avium infection
at the age of 2 y. He was 10 y old as of June 2005 and well. P2 had high
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adenovirus, parainﬂuenza virus (I and III), and inﬂuenza virus (A and
B). His father was hospitalized at the age of 25 y for a fever of
unknown origin. He recovered on antibiotic treatment and was 39 y
old as of June 2005 and well. He had been vaccinated with BCG in
infancy, with no adverse effect. P29s paternal grandfather developed
tuberculosis at the age of 20 y and recovered only after 5 y of
hospitalization and antibiotic treatment in the 1950s. He died at the
age of 50 y in unknown circumstances. P29s half-brother has
remained healthy and was 2.5 y old as of June 2005. The medical
histories of P3, P4, and P5 have been described elsewhere [17,36,37].
P3 is heterozygous for the L706S STAT1 mutation and developed
BCG-osis after vaccination in childhood, but recovered after speciﬁc
antibiotic therapy. P4 was homozygous for the 1758_1759delAG
STAT1 mutation. He developed BCG-osis at the age of 2 mo, which
was in remission after antibiotic treatment, followed by recurrent
HSV-1 encephalitis from the age of 12 mo until his death at the age of
16 mo. P5 is homozygous for the 1928insA STAT1 mutation. He
developed BCG-osis after vaccination. His genetic, immunological,
and clinical features have been reported elsewhere [37]. Informed
consent was obtained from all patients and their relatives included in
the study.
Molecular representation of STAT1 phosphodimers. Models (3-D)
of STAT1 mutants E320Q, Q463H, and L706S were built with
Modeller software [49]. The X-ray crystallographic structures of
STAT1 [32] and STAT3b [50] dimers, available as Protein Data Bank
(PDB) entries 1BF5 and 1BG1, were used as templates for
comparative modeling [51]. These structures were determined at
resolutions of 2.9 and 2.25 A ˚ , respectively, with stretches of missing
residues corresponding to regions of low electron density. Before
constructing the mutant representations, we therefore built a
representation of a complete STAT1 dimer (residues 136–710). We
visualized and analyzed 3-D structures with MOLMOL [52].
Cell culture and stimulation, DNA and RNA extraction, PCR,
sequencing, and Northern blotting. EBV-transformed B cells and
SV40-transformed ﬁbroblast cells were cultured as previously
described [36]. The parental 2C4 ﬁbrosarcoma cell line and its
STAT1-deﬁcient U3C-derived cell line [53] were cultured in RPMI
1640 medium supplemented with 10% heat-inactivated bovine fetal
serum (GIBCO-BRL, Paisley, Scotland, United Kingdom). STAT2-
deﬁcient U6A cells (derived from the 2fTGH parental ﬁbrosarcoma
cell line) [54] were cultured in DMEM supplemented with 10% fetal
calf serum. Stimulations were performed with the indicated doses of
IFNG (Imukin, Boehringer Ingelheim, Germany) and IFNA2b
(IntronA; Schering Plough, Innishannon, Ireland). Genomic DNA
and total RNA were extracted from cell lines, fresh blood cells, or
tissue biopsy specimens as previously described [36]. Genomic DNA
and cDNA were ampliﬁed and sequenced as previously described [36].
Primers and PCR conditions are available upon request. Northern
blotting was performed as previously described [36]. Sarcoma ﬁ-
broblast cells were stimulated with 10
5 IU/ml IFNA or IFNG. The
nylon membrane was probed with radiolabeled IRF1, ISG15, STAT1,
and GADP probes (sequences available upon request).
Determination of mRNA levels by relative Q-RT-PCR. Total RNA
was extracted with Trizol reagent (Invitrogen, Paisley, Scotland,
United Kingdom) from EBV-transformed B cells or sarcoma
ﬁbroblasts left unstimulated or stimulated with 10
5 IU/ml IFNA or
IFNG. RNA was treated with RNase-free DNase (Roche Diagnostics
France, Meylan, France) and cleaned by passage through an RNeasy
column (Qiagen S.A. France, Courtaboeuf, France). RNA was then
reverse transcribed directly with Oligo-dT, using the TaqMan Reverse
Transcription kit (Applied Biosystems, Courtaboeuf, France; and
Roche Diagnostics France), for the determination of MX1, ISG15, and
IRF1 mRNA levels using the Taqman probes delivered by Applied
Biosystems France for these genes. The results were normalized with
values for the endogenous GUS cDNA.
Expression vectors and stable transfection. The mutated STAT1
alleles were inserted into an M2-tagged pcDNA3-STAT1 vector (a gift
from M. J. Holtzman [17]) using the Quickchange site-directed
mutagenesis kit (Stratagene, La Jolla, California, United States),
following the manufacturer’s instructions. U3C cells were cotrans-
fected with one of the various STAT1 M2-tagged pcDNA3 vectors or
an insertless M2-tagged pcDNA3 vector (mock) and the pcDNA3
zeocin-resistant vector, using Lipofectamine 2000 reagent (Invitro-
gen). The cells were diluted (1:10) 24 h after transfection, and selected
48 h after transfection by culture on medium containing 200 lg/mL
zeocin for 10 days, followed by ﬁve days of culture on medium
containing 1,000 lg/mL zeocin. Living cells were picked and screened
by immunoﬂuorescence staining with a STAT1-speciﬁc antibody. The
pmock clone was selected by pcDNA3 PCR ampliﬁcation. The
populations selected were then cloned by the limiting dilution
method. After 1 mo of culture, cells were transferred to medium
without zeocin.
EMSA. EMSA was carried out as previously described [36]. Brieﬂy,
cells were stimulated by incubation for 30 min with 10
5 IU/ml IFNG
or IFNA. We incubated 5–40 lg of nuclear extract with
32P-labeled
(adATP) GAS (from the FCGR1 promoter) or ISRE (from the ISG15
promoter) probes and subjected the mixture to electrophoresis in a
polyacrylamide gel. The additional GAS probes used were taken from
the M67 promoter 59-GATCCATTTCCCGTAAATCATGATC-39 and
from the IRF1 promoter 59-CTGATTTCCCCGAAATGA-39.
Immunoprecipitation and Western blotting. Cells were left
unstimulated or were stimulated by incubation with 10
5 IU/ml IFNG
or IFNA for 30 min. For STAT1 immunoprecipitation, whole-cell
protein extracts were prepared as previously described [36]. The cell
lysates were subjected to immunoprecipitation using SigmaPrep spin
columns (Sigma MC1000; Sigma, Saint Louis, Missouri, United States)
and 2 lg of anti-STAT1 antibody (TEBU C-111) with 30 lL of protein
G (P-3296; Sigma). We washed the immunoprecipitates according to
the manufacturer’s instructions, and processed them for Western
blotting. Western blotting was performed as previously described
[36]. The following antibodies were used: anti-phospho-STAT1 (9171;
Cell Signaling Technology), anti-STAT1 (610116; BD Transduction
Laboratories, San Diego, California, United States), anti-STAT3 (sc-
7179; Santa-Cruz Biotechnology, Santa Cruz, California, United
States), anti-phospho-STAT2 (4441; Cell Signaling), and anti-STAT2
(sc-476; Santa-Cruz Biotechnology, Santa Cruz, California, United
States). Biotinylated peptides were immunoprecipitated as previously
described [30]. They were synthesized by Sigma Genosys and
immunoprecipitated with streptavidin-agarose (15942–050; Invitro-
gen). The STAT1 antibody was used for Western blotting, as
previously described [36].
Immunoﬂuorescence. Immunoﬂorescence staining was carried out
as previously described [17]. The primary antibody was a mouse anti-
STAT1 antibody (610116; BD Biosciences, San Diego, California,
United States) (1/100 dilution for SV40-transformed ﬁbroblasts and 1/
700 dilution for ﬁbrosarcoma clones), and the secondary antibody
was an Alexa-488–conjugated goat antimouse IgG (Molecular Probes,
Eugene, Oregon, United States) (1/300 dilution for SV40-transformed
ﬁbroblasts and 1/1000 dilution for ﬁbrosarcoma clones). The isotypic
control was a mouse isotypic antibody (555746; BD Biosciences).
Immunoﬂuorescence was detected with a Zeiss Axioplan 2 micro-
scope (Zeiss, Oberkochen, Germany).
Whole-blood assay of the IL12–IFNG circuit. Whole-blood assays
were performed as previously described [41]. Heparin-treated blood
samples from P1, P2, and P3 and their respective controls were
stimulated in vitro with BCG alone or with BCG plus IFNG or IL12.
Supernatants were collected after 18 and 72 h of stimulation and
ELISA was performed with speciﬁc antibodies directed against IFNG,
or IL12p70, using the human Quantikine IL12p70 HS and the human
Pelipair IFNG kit from Sanquin (Amsterdam, the Netherlands),
according to the manufacturer’s guidelines.
Viral assays. Viral assays were performed as previously described
[36]. Brieﬂy, skin-derived SV40-transformed ﬁbroblasts, 2C4 and U3C
ﬁbrosarcoma cells, and U3C ﬁbrosarcoma–derived clones were left
untreated or were treated with 10
5 IU/mL IFNG for 24 h. They were
then infected by incubation with various titers of HSV or VSV for 48
h. Viral titers were then determined by visualizing the lysed wall.
Supporting Information
Figure S1. GAS-Binding Protein upon IFNA Stimulation
EMSAs with the radiolabeled GAS probe of nuclear extracts (5 lg)
from patient’s EBV-B cells (A) or from a parental ﬁbrosarcoma cell
line (2C4) and STAT1-deﬁcient U3C ﬁbrosarcoma cell clones,
untransfected (U3C) or stably cotransfected with a zeocin-resistance
vector and a vector containing a mock, WT, E320Q, Q463H or L706S
STAT1 alleles (B and C). The cells were not stimulated (NS) or were
stimulated for 30 min with 10
5 IU/ml IFNA (A–C) or IFNG (C). For (A–
C), one experiment representative of two to ﬁve independent
experiments is shown.
Found at DOI: 10.1371/journal.pgen.0020131.sg001 (821 KB TIF).
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(3593); IL12RB1 (3594); IRF1 (3659); MX1 (4599); ISG15 (9636).
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